Pediatric Patients Children (<6 years): Safety and effectiveness have not been established. Children (6-12 years): An initial dose of 75 mg once daily is reasonable. Patients requiring further reduction in blood pressure should be titrated to 150 mg once daily (see PRECAUTIONS: Pediatric Use). Adolescent patients (13-16 years): An initial dose of 150 mg once daily is reasonable. Patients requiring further reduction in blood pressure should be titrated to 300 mg once daily. Higher doses are not recommended (see PRECAUTIONS: Pediatric Use). Volume- and Salt-depleted Patients A lower initial dose of AVAPRO (75 mg) is recommended in patients with depletion of intravascular volume or salt (e.g., patients treated vigorously with diuretics or on hemodialysis) (see WARNINGS: Hypotension in Volume- or Salt-depleted Patients). HOW SUPPLIED AVAPROŽ (irbesartan) is available as white to off-white biconvex oval tablets, debossed with a heart shape on one side and a portion of the NDC code on the other. Unit-of-use bottles contain 30, 90, or 500 tablets and blister packs contain 100 tablets, as follows: 75 mg150 mg300 mgDebossing277127722773Bottle of 300087-2771-310087-2772-310087-2773-31Bottle of 900087-2771-320087-2772-320087-2773-32Bottle of 500-0087-2772-150087-2773-15Blister of 100-0087-2772-35- Storage Store at a temperature between 15° C and 30° C (59° F and 86° F) [USP]. Distributed by: Bristol-Myers Squibb Sanofi-Synthelabo Partnership New York, NY 10016 J4-641H 1092944A6 Revised August 2002 | ||||
Email this article
Printer friendly
Bookmark this pageadvertisement
